RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Eisai and Merck/MSD announced the China National Medical Products Administration (NMPA) approved Lenvima® (lenvatinib) as a first-line treatment for unresectable hepatocellular carcinoma. It is the first China approval for Lenvima, where the incidence of HCC is high, and the first new systemic therapy approved in China for first-line treatment of unresectable HCC in ten years. The NMPA completed its review in 10 months under Priority Review procedures.
Source: China Biotoday
